Opinion|Videos|October 21, 2024
Balancing Efficacy Outcomes With Tolerability and Quality of Life in First-Line mRCC Treatment Decisions
Author(s)Rana R. McKay, MD
Panelists discuss how they balance efficacy outcomes like overall survival and progression-free survival against tolerability and quality of life considerations when making decisions about first-line treatment for metastatic renal cell carcinoma patients.
Advertisement
Episodes in this series
- How do efficacy outcomes, such as overall survival and progression-free survival, compare with tolerability and quality of life in your decision-making process for first-line metastatic renal cell carcinoma treatment?
Advertisement
Related to this article
Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.
FDA approves belzutifan plus lenvatinib for advanced clear cell RCC after PD-1/PD-L1 therapy, based on PFS and response rate benefit vs cabozantinib.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Rusfertide Redefines the Polycythemia Vera Paradigm
2
FDA Grants Fast Track Designation to TRE-515 for KRAS G12C NSCLC
3
Pirtobrutinib Gains FDA Approval for Frontline CLL/SLL in Select Patients
4
Extended Survival Raises New Questions on Imaging and Treatment Intensification in ROS1+ NSCLC
5